All In Biotech

NDA 021368 · Lilly

Cialis

Tadalafil · Oral · Phosphodiesterase 5 Inhibitor

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Feb 15, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Nov 21, 2003

Approved uses

6

Original approval plus efficacy supplements

Registered trials

259

70 Phase 3, 23 recruiting

FAERS reports

55,369

31,408 serious, 3,985 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 3, 2026.

CIALIS ® is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of: erectile dysfunction (ED) ( 1.1 ) the signs and symptoms of benign prostatic hyperplasia (BPH) ( 1.2 ) ED and the signs and symptoms of BPH (ED/BPH) ( 1.3 ) If CIALIS is used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks ( 1.4 ). 1.1 Erectile Dysfunction CIALIS ® is indicated for the treatment of erectile dysfunction (ED). 1.2 Benign Prostatic Hyperplasia CIALIS is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). 1.3 Erectile Dysfunction and Benign Prostatic Hyperplasia CIALIS is indicated for the treatment of ED and the signs and symptoms of BPH (ED/BPH). 1.4 Limitation of Use If CIALIS is used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks because the incremental benefit of CIALIS decreases from 4 weeks until 26 weeks, and the incremental benefit of CIALIS beyond 26 weeks is unknown [see Clinical Studies ( 14.3 )] .

Mechanism: Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) enhances erectile function by increasing the amount of cGMP. Tadalafil inhibits PDE5. Because sexual stimulation is...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • CIALIS · TADALAFIL 20MG · TABLET, ORAL · Prescription · TE AB1
  • CIALIS · TADALAFIL 5MG · TABLET, ORAL · Prescription · TE AB1
  • CIALIS · TADALAFIL 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued · TE AB1
  • CIALIS · TADALAFIL 10MG · TABLET, ORAL · Prescription · TE AB1

Clinical trials

Interventional ClinicalTrials.gov studies with "Tadalafil" as an intervention, any sponsor and status, largest first.

All 259 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • headache5,379
  • drug ineffective5,165
  • dyspnoea4,744
  • diarrhoea3,734
  • fatigue3,414
  • nausea3,135
  • dizziness2,652
  • cough2,294
  • asthenia2,034
  • off label use1,991
  • back pain1,779
  • pain1,775

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,183
20051,297
2006974
2007324
2008370
2009493
2010599
2011733
2012732
2013740
20141,105
20156,447
20162,071
20171,785
20182,440
20194,154
20203,448
20213,349
20224,020
20234,681
20244,980
20255,648
20263,796

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cialis (Tadalafil)

2024 spending

$3.7M

Beneficiaries

1,510

7,402 claims

Per beneficiary

$2,443

$9.68 per unit

View as table
YearSpending
2020$11,236,630
2021$8,146,168
2022$6,874,548
2023$6,079,747
2024$3,689,347

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 565 on PubMed

Sponsor: Eli Lilly

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.